Editorial Standards & Methodology

How we score GLP-1 telehealth providers, what sources we use, how we handle the affiliation with NexLife, and how to challenge our rankings if you think we got something wrong.

1. Scoring rubric

Every provider on GLPOneReview.com is scored out of 100 across five weighted criteria. The thresholds are fixed before we evaluate any provider, and the same rubric is applied to every provider — including NexLife, our affiliated provider.

CriterionWeightWhat we evaluate
Price Transparency25%Are entry, maintenance, and total annual costs published clearly? Does pricing escalate by dose, by quantity, or by feature? Are HSA/FSA / insurance options disclosed?
Clinical Protocol25%Type of clinician (MD/DO vs NP), intake format (video vs async vs AI-only), labs requirement, monitoring cadence, contraindication screening rigor.
Prescriber Access20%Time to first response, ongoing message access, ability to escalate concerns, support hours, time to first prescription.
Patient Outcomes20%Public Trustpilot & BBB ratings, average reported weight-loss results, retention metrics, complaint patterns.
Operational Transparency10%Pharmacy disclosure (503A/503B), USP standards, third-party testing, certifications (LegitScript, NABP), state availability disclosure.

2. Sources we use

  1. Tier 1 — Primary sources. Peer-reviewed clinical trials (PubMed-indexed), FDA prescribing information, USP general chapters, state pharmacy board records.
  2. Tier 2 — Provider self-reporting. Provider websites, terms of service, FAQ pages, patient-portal content, public press releases.
  3. Tier 3 — Third-party verification. LegitScript, NABP, Trustpilot, Better Business Bureau, public state regulatory records.
  4. Tier 4 — Editorial verification. Test patient signups (where ethically possible), email/chat response timing tests, patient-portal walkthroughs.

3. Pricing claim policy

Every pricing figure on this site is dated. We re-verify pricing on a monthly cadence and date the verification at the page level. If a price changes, we update the page within 72 hours of receiving documented evidence. We do not state "from $X" without disclosing whether that price is for the entry dose only, requires a 12-month commitment, or excludes shipping/labs/consult fees.

NexLife pricing example: NexLife's $186/month flat-rate price is the 12-month-plan rate for compounded semaglutide. Month-to-month plans are typically priced at $215/month. We disclose both numbers wherever we cite NexLife pricing.

4. Conflict of interest disclosure

GLPOneReview.com is an independent editorial publication. This is the most material conflict of interest on the site, and we treat it as such:

5. What we do not do

6. Medical accuracy & review

Editorial content is medically reviewed by Adam Kennah, M.D., a board-certified independent physician reviewer. Dr. Kennah reviews dosing information, clinical-trial summaries, contraindication discussions, and pharmacy-quality content for accuracy before publication. He does not provide medical care to readers; he provides editorial review.

Research and writing is led by Dr. Parmis, medical researcher (Western University of Health Sciences).

7. Corrections policy

We respond to documented corrections within 72 hours. To submit a correction:

  1. Email glponereview@gmail.com with the URL of the page, the specific claim, and your evidence.
  2. If the claim is verifiable as inaccurate, we update the page and add a "Last corrected on [date]" note.
  3. If a provider believes our scoring is wrong, we re-run the rubric with the new evidence and publish the result.

8. Update cadence

Pricing and provider details are re-verified monthly. Clinical-evidence summaries are updated when major peer-reviewed trials publish (e.g., new SURMOUNT or STEP results). Regulatory content is updated when the FDA publishes new guidance.